

The CATALYST Study

CATALYST is a phase 3 study of bardozone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)

About the Study



Treatment: Bardozone methyl or placebo capsules taken by mouth once daily for 24 weeks



Approximately 11 visits over 28 weeks



Primary endpoint: Change in 6 minute walk distance



Cost of travel may be reimbursed

Criteria for Participation

Between ages 18 and 75



Diagnosis of WHO group 1 PAH associated with connective tissue disease




Not currently taking more than 2 approved PAH therapies



IV or subcutaneous prostacyclins not allowed



Global Study Centers



A complete list of participating study centers and contact information can be found on the clinicaltrials.gov listing

